Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Sponsor: CSL Behring
This PHASE2 trial investigates Rheumatoid Arthritis and is currently completed. CSL Behring leads this study, which shows 12 recorded versions since 2012 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jun 2021 — Jul 2024 [monthly]
Completed PHASE2
-
May 2021 — Jun 2021 [monthly]
Completed PHASE2
▶ Show 7 earlier versions
-
Jan 2021 — May 2021 [monthly]
Completed PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Aug 2020 [monthly]
Completed PHASE2
-
May 2018 — Jun 2018 [monthly]
Completed PHASE2
-
Oct 2017 — May 2018 [monthly]
Completed PHASE2
-
Feb 2017 — Oct 2017 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Jun 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CSL Behring
For direct contact, visit the study record on ClinicalTrials.gov .